Artivion (AORT) to Release Quarterly Earnings on Thursday

Artivion (NYSE:AORT) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.03 per share for the quarter. Artivion has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The company had revenue of $98.02 million during the quarter, compared to analysts’ expectations of $97.70 million. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Artivion Trading Up 1.6 %

Shares of NYSE:AORT opened at $27.91 on Wednesday. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -132.90 and a beta of 1.75. Artivion has a 12 month low of $13.18 and a 12 month high of $29.24. The company’s fifty day simple moving average is $26.06 and its 200 day simple moving average is $25.00. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07.

Insider Buying and Selling

In related news, CAO Amy Horton sold 12,430 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the transaction, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Anthony B. Semedo sold 9,709 shares of Artivion stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the transaction, the director now directly owns 34,159 shares in the company, valued at approximately $853,633.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,109 shares of company stock worth $951,935. Corporate insiders own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on AORT shares. Stifel Nicolaus upped their price objective on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. JMP Securities initiated coverage on Artivion in a research note on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price target on shares of Artivion in a research note on Friday, September 27th. Finally, Oppenheimer lifted their price objective on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $30.60.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.